Repros Therapeutics — Investor Presentation (July 2013)
30 slides from Repros Therapeutics's investor presentation, Jul 9, 2013

Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders
Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from the results expressed

Slide 3: Investment Highlights
Investment Highlights • Focused strategy: small molecule therapeutics for reproductive disorders • Two late stage clinical programs each with +$1B sales potential • Androxal ® : PHASE 3 (SPA) oral treatment for Low Testosterone – Patented and pending patent’s life to the mid 2020’s – Growing +$2B ma

Slide 4: Testosterone Market and Androxal Overview
Testosterone Market and Androxal Overview • US market for low testosterone exceeds $1.5 billion • Only approved non invasive therapies are hormone replacements • Repros believes 85% of hypogonadal men experience low T due to an endocrine disorder – These men have functional but un - stimulated teste

Slide 5: Who are the men using testosterone?
Who are the men using testosterone? European Male Aging Study Distribution and Selected Characteristics of Men Ages 40 - 79 ( Tajar et al) 0 10 20 30 40 50 60 70 80 90 100 Eugonadal Secondary Hypogonadal Primary Compensated Hypogonadism % of Subjects Age: 58.5 (10.7) BMI: 27.3 TT: 513.4 ng / dL LH:

Slide 6: Androxal Exhibits Patient Reported Effects Equivalent to Androgel
Androxal Exhibits Patient Reported Effects Equivalent to Androgel ZA - 003 Type C FDA Meeting Q4 - ’07 Unacceptable Endpoint for Phase 3 0 5 10 15 20 25 30 Androxal Androgel IIEF Score Baseline 6 mos. Androxal approaches statistical significance p=0.08 compared to baseline and Androgel change 0 2 4

Slide 7: Type C Meetings Lead to SPA on First Pass
Type C Meetings in 1Q10, 3Q10 & 2Q12 ZA - 203 Lead to SPA on 1 st Pass Repros Convinces FDA Exogenous T Suppresses Pituitary Hormones and Testicular Function 0 2 4 6 8 10 12 14 12.5 mg 25 mg PL Testim FSH Treatment Effect of Treatment on Median FSH p versus Testim Before After p<0.00001 p=0.0004 0 1

Slide 8: FDA Accepts Phase 3 Protocols Under an SPA
FDA Accepts Phase 3 Protocols Under an SPA Goal to Submit NDA Mid 2014 • Phase 3 pivotal studies being conducted under SPA – 2 identical trials (BMI > 25, Age ≤ 60) • 152 subjects in each trial (114 on Androxal , 38 on placebo) – Men with morning T<300 ng / dL assessed twice on two separate days – M

Slide 9: ZA-301: Androxal Improves T without Affecting Sperm
ZA - 301: Androxal Improves T without Affecting Sperm 0 50 100 150 200 250 300 350 400 450 Androxal Placebo Total T ( ng / dL ) Baseline End of Study 83 % in Normal Range 79% in ITT 0 10 20 30 40 50 60 Baseline End of Study Sperm Concentration X 106 Placebo Androxal Androxal Up-titration No statisti

Slide 10: ZA-300: % of Men with T in the Normal Range
ZA - 300: % of Men with T in the Normal Range Fully Enrolled 0 10 20 30 40 50 60 70 80 90 100 Week 26 % Normal N=334 As of 6/12/13 86% Normal Normal Range = 300 – 1040 ng / dL Up - titration if morning T <450ng/ dL ~50% up - titrated 9

Slide 11: Phase III Androxal Program Status
Phase III Androxal Program Status NDA Target: Mid 2014 Study Target Enrollment Study Duration Subjects Screened Subjects Enrolled Projected Full Enrollment Top Line Results ZA - 300 Safety 500 6 months 1288 (28 sites) 500 Fully Enrolled Q4 2013 ZA - 301 Pivotal 152 3 months (+ 6 weeks) 571 (17 sites

Slide 12: Androxal Safety Treatment Emergent Adverse Events
Androxal Safety Treatment Emergent Adverse Events Studies 301, 300, and 303 Study 301 Study 300 Study 303 Preferred Term 12.5 mg (%) 25 mg (%) PBO (%) 12.5 mg (%) 25 mg (%) 12.5 mg (%) 25 mg (%) PBO (%) N 90 22 37 259 240 94 69 104 Any Event 28 23 24 38 44 19 39 30 Upper respiratory infection 6 5 0

Slide 13: Effects of Androxal on Bone Markers and Mineral Density
Effects of Androxal on Bone Markers of Bone Turnover & Mineral Density Suggests Androxal Strengthens Bone 12

Slide 14: Androxal NDA Timeline
Androxal NDA Timeline Q4 2013 Q1 2014 Q2 2014 Q3 2014 NDA ZA - 302 ZA - 300 - F inal Safety Data for ISS ISE Pre - NDA Meeting 13

Slide 15: How do we maximize shareholder return?
How do we maximize shareholder return? • All Repros Assets are Unencumbered • Androxal asset should be +90% de - risked during Q1 - ’14 • Androxal should open T treatment into primary care – License • Royalty rate commensurate with market penetration (20 – 30%) • Inevitable take - out by big pharma

Slide 16: Market Analysis: Total Prescriptions for Hormone Therapies Across All MDs
Market Analysis O ouinTILes’ Total Prescriptions for Hormone Therapies Across All MDs Across all physician specialties, androgen hormone prescriptions have been growing more than 20% per year and now total almost 7.5 million per year. TRXs for All MDs Af, tae tLe Es SSE se SSP Pe PPP PPP “®-52151 HO

Slide 17: Market Analysis: Hormone Therapy Prescriptions for Endocrinologists
Market Analysis QO ouintTILes’ Total Prescriptions for Hormone Therapies For Endocrinologists Endocrinologists prescriptions have grown ~15-18% per year and now total 800,000 TRXs annually. Thus, endos write a little less than 10% of all androgen hormone prescriptions. TRXs for Endos -®-52151 HORMON

Slide 18: Market Analysis: Scenario Forecast Assumptions
Market Analysis O auintTies’ Scenario 1 Forecast Assumptions Quintiles has attempted to be conservative in most assumptions to test the feasibility of this targeted approach. + 90% of androgen hormone prescriptions + Conservative annual overall TRx growth of ~8% Prescriptions + Likely understated on

Slide 19: Market Analysis: Scenario Forecast
Market Analysis Q auinTiLes’ Scenario 1 Forecast Based on conservative TRX growth assumptions, market share at 33%, and a slight price premium, Androxal generates more than $100 million per year. PN | sesase | senso | ensta | ssaee | sens | ras | evearr | rasa | senso | secre | emacs | oes | roar |

Slide 20: Proellex for the Treatment of Uterine Fibroids and Endometriosis
Proellex for the Treatment of Uterine Fibroids and Endometriosis • Over 30 million women of reproductive age in the US afflicted with symptomatic uterine fibroids or endometriosis • Over 300,000 hysterectomies performed every year in the US to treat these two disorders • No acceptable chronic therap

Slide 21: An Effective Dose of Proellex Stops Menstruation in Majority of Women
An Effective Dose of Proellex Stops Menstruation in Majority of Women 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea Mimics early follicular phase Without progesterone 20

Slide 22: Proellex Eliminates the Pain and Need for Analgesics in Endometriosis
Proellex Eliminates the Pain and Need for Analgesics to Control the Pain of Endometriosis 0 10 20 30 40 50 60 70 Placebo Proellex 25mg Proellex 50 % of Baseline p - value versus placebo 25 mg = 0.001 50 mg = 0.017 55.5 22.2 13.6 0 10 20 30 40 50 60 70 80 90 100 Placebo 25mg Proellex 50mg Proellex %

Slide 23: Phase 2 Endometriosis Study
ZPE - 202 Phase 2 Endometriosis Study • 90 subject double blind placebo controlled study balanced between placebo, 6 and 12 mg oral Proellex – Subject population (confirmed endometriosis) • Severe endometriosis as determined by BBSS score • Requiring narcotics or prescription analgesics to control e

Slide 24: Vaginal Proellex to Eliminate the Need for Hysterectomy
Vaginal Proellex to Eliminate the Need for Hysterectomy in Most Situations • Initial Phase 2 study tested four doses of vaginal administration in the treatment of uterine fibroids completed – Assess reduction of fibroid size and elimination of symptoms – Top line data reported • FDA requires additio

Slide 25: Systemic Exposure to Oral Proellex Varies in a Dose Dependent Manner
Systemic Exposure to Oral Proellex Varies in a Dose Dependent Manner Significant reduction in exposure via vaginal delivery 0 200 400 600 800 1000 1200 1400 1600 1800 12 mg vaginal 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg Concentration ( ng /ml) Combined Cmax for Telapristone and Primary Metabolite Liv

Slide 26: Vaginal Proellex (ZPV-200) Uterine Fibroid Quality of Life
Vaginal Proellex (ZPV - 200) Uterine Fibroid Quality of Life – UFS QOL 25 12 mg dose significantly improves all symptoms of uterine fibroids

Slide 27: Vaginal Proellex (ZPV-200) PBAC Scores Over Time
Vaginal Proellex (ZPV - 200) PBAC Scores Over Time PBAC Score >80 = menorrhagia 26 12 dose significantly improves excessive menstrual bleeding due to fibroids

Slide 28: ZPV-Ext. Proellex Open Label Update (12mg dose)
ZPV - 200 Ext. Proellex Open Label Update (12mg dose) 0 10 20 30 40 50 60 70 80 90 100 Baseline End of 1st Cycle End of 2nd Cycle % of Initial Volume 12mg in initial treatment (n=15 fibroids) 3 or 6mg in initial treatment (n=14 fibroids) Paired Comparison for Subjects Dosed at 12 Throughout Study •

Slide 29: Projected Income Through 2016
Projected Income Through 2016 (in millions) 2014 2015 2016 Total Net Revenue - $5.0 $63.0 $68.0 Expenses: R&D Androxal $7.5 - - $7.5 R&D Proellex $8.0 $15.5 $14.5 $38.0 Sales & Marketing $2.0 $14.0 $23.0 $39.0 General Corporate $6.0 $10.0 $11.5 $27.5 Net Income (EBITDA) $(23.5) $(34.5) $14.0 $(44.0)

Slide 30: Financial Summary
Financial Summary • Cash and equivalents (as of 6/30/13 - unaudited) $87.7 M • Cash runway: 2016 – Both drugs’ NDAs filed – Anticipate Androxal approved • Current shares outstanding: 23.0 M shares – Warrants Outstanding – Series A – 877,137 (purchased in unit deal @ $2.45); Series B – 810,109 @ $2.4
Source: SEC EDGAR · 8-K filed Jul 9, 2013
More decks from Repros Therapeutics
Investor Presentation (September 2017)16 slides · Sep 11, 2017
Investor Presentation (May 2017)16 slides · May 17, 2017
Investor Presentation (May 2017)16 slides · May 2, 2017
Investor Presentation (November 2016)37 slides · Nov 15, 2016
Investor Presentation (September 2016)26 slides · Sep 12, 2016
Investor Presentation (August 2016)34 slides · Aug 18, 2016